Our Science

21314542_1782525265371215_704094325341772015_n.jpg
 
 

The Endocannabinoid System

 

The human body interacts with cannabis in the endocannabinoid system, a network of neurotransmitters and receptors found in the brain and central nervous system of every human, and whose purpose is to regulate the body’s homeostasis throughout the rest of its systems.

 

The active compounds of the cannabis plant, the cannabinoids, mimic the body’s naturally occurring neurotransmitter lipids in molecular structure, thus allowing them to bind to the receptor sites as if they were the body’s naturally occurring (endogenous) neurotransmitters. Because the molecular structures of these endogenous neurotransmitters mimic those of cannabinoids, the pioneering researchers of cannabis’ interaction in the human body named the neurotransmitters endocannabinoids.

 

These researchers have identified two primary receptor site proteins in the endocannabinoid system: CB1, found in greatest abundance in the brain and also in peripheral organs, and CB2, found in greatest abundance in the immune system and also throughout the central nervous system. CB1 receptors play an important role in motivation and cognition, while CB2 receptors play an important role in the body’s immunity, prevention, protection, and repair from harmful invading proteins.

 

This plant medicine is such an effective and unique treatment because cannabinoids bind to these receptor sites as if they were an endogenous neurotransmitter, and also bind to the neurotransmitters and other parts of the endocannabinoid system. Delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) bind to the same receptor sites as the endogenous neurotransmitters anandamide (AEA), found in the brain, and 2-arachidonoyl glycerol (2-AG), found in the peripheral nervous system.

 

 

The Canna DNA Kit

 

The CANNA DNA kit uses single nucleotide polymorphisms (SNPs) to identify the locations in an individual’s DNA strands that characterize how he or she metabolizes endocannabinoids and other endogenous or exogenous compounds.  

 

This study of how genes affect a person’s response to drugs, known as pharmacogenomics, is a relatively new field, combining pharmacology and genomics to develop effective, safe medications and doses tailored to a person’s genetic makeup (2).

 

Earth Healthcare has identified how endocannabinoids, such as AEA and 2-AG, and exogenous cannabinoids, such as THC and CBD, work in conjunction and also in lieu of each other to create balance in the body (homeostasis). It has also identified 10 metabolic and catabolic compounds responsible for production, regulation, and degradation of endogenous ligands, molecules that play a major role in a person’s endocannabinoid levels.

 

As part of this patent-pending research, Earth Healthcare has identified the SNPs in a person’s genealogy that characterize the production, regulation, and degradation of these molecules. Our database of findings enables us to identify - at these SNP sites - genomic irregularities or imbalances, as well as each person’s response to THC, CBD, and combinations of cannabinoids, in conjunction with specific terpenes and other natural and pharmaceutical medications.